NCT04100694Approved For Marketing不适用
Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Merus N.V.
研究概览
简要总结
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128 clinical trial or have other considerations that prevent access to MCLA-128 through an existing clinical trial. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual's medical history and program eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older
- •At least one evaluable or measurable lesion according to RECIST v1.1
- •Patient with advanced metastatic solid tumor with documented NRG1 fusion determined in a qualified local laboratory by molecular profiling using methods such as next generation sequencing [DNA or RNA] as routinely performed at CLIA or other similarly-certified laboratories.
- •Treatment with anticancer medications or investigational drugs within the following intervals before the first administration of MCLA-128:
- •At least 14 days for chemotherapy, targeted small molecule therapy, or radiation therapy OR
- •At least 5 half-lives have passed since discontinuation of the systemic treatment
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- •Adequate organ function at the time of initiation of treatment administration
- •Negative pregnancy test results in women of childbearing potential (defined as women ≤50 years of age or history of amenorrhea for ≤12 months prior to study entry)
- •Ability to give written, informed consent prior to treatment, with the understanding that the consent may be withdrawn by the patient at any time without prejudice
- •Not eligible or feasible to participate in a clinical trial
- •Any condition that in the opinion of Merus may preclude appropriate use of the investigational medicine
排除标准
- •Any untreated, symptomatic central nervous system (CNS) lesion
- •Presence of an active and uncontrolled infection
- •Leptomeningeal metastases
- •Known hypersensitivity to any of the components of MCLA-128 or history of severe hypersensitivity reactions to human or humanized monoclonal antibodies, including therapeutic antibodies
- •Presence of LVEF <50% on the screening echocardiogram; or history or presence of any significant cardiovascular disease, including unstable angina or myocardial infarction within 12 months prior to treatment, congestive heart failure (NYHA Class III or IV), or ventricular arrhythmia requiring medication
- •Presence of any other medical or psychological condition deemed by the Physician to be likely to interfere with a patient's ability to sign informed consent, cooperate or participate in the study, or interfere with the interpretation of the results.
研究者
相似试验
Approved For Marketing
不适用
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye DiseaseGraves' OrbitopathyThyroid Eye DiseaseNCT04040894Amgen
Unknown
3 期
Precise Therapy for Refractory HER2 Positive Advanced Breast CancerHER2+ Breast CancerNCT05429684First Affiliated Hospital Xi'an Jiaotong University120
撤回
1 期
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsGastroesophageal Junction AdenocarcinomaBreast CancerGastric CancerNCT05678205Artiva Biotherapeutics, Inc.133
Unknown
1 期
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive SystemGallbladder CancerPancreatic CancerGastric CancerEsophageal CancerBowel CancerLiver CancerNCT02662348Yi Miao6
进行中（未招募）
1 期
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid TumoursTriple Negative Breast CancerCastration-resistant Prostate CancerRAS Wild Type Colorectal CancerEndometrial CancerHepatocellular Carcinoma (HCC)Non-small Cell Lung Cancer (NSCLC)Oesophageal CancerOvarian CancerMelanomaCervical CancerBladder CancerSquamous Cell Cancer of the Head and NeckPancreatic CancerGastric CancerNCT05057013Cancer Research UK81